Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE)Axel Grothey, M. Kozloff, Eric Hedrick et al.|Journal of Clinical Oncology|2007Cited by 55